

October 2, 2017

Company name: Mitsubishi Tanabe Pharma Corporation  
Representative: Masayuki Mitsuka  
President and Representative Director  
Code number: 4508, First Section, Tokyo Stock Exchange  
Contact: Yoshifumi Mifune, General Manager,  
Corporate Communications Department  
TEL: +81-6-6205-5211

**Completion of Transfer of Shares of Generic Drugs Subsidiary  
(Update of Previous Disclosure)**

Mitsubishi Tanabe Pharma Corporation (hereinafter, “MTPC”) completed the transfer of all shares of Tanabe Seiyaku Hanbai Co., Ltd. (hereinafter, “TSH”) to Nipro Corporation (hereinafter, “Nipro”) as scheduled on October 1, 2017, which was announced in “Split off and Transfer of Generic Drugs and Part of Long-Listed Products Business and Change of Subsidiary” dated March 28, 2017.

Due to this share transfer, TSH has been renamed Nipro ES Pharma Co., Ltd. as of October 1, 2017.

The impact of the transfer of shares on MTPC’s consolidated results had already been incorporated in the forecast of consolidated results for the fiscal year ending March 31, 2018, which was announced in “Financial Results for the Fiscal Year ending March 31, 2017 (IFRS)” dated May 10, 2017.

End